The Institute of Clinical Research (ICR) has announced a specialist insurance and professional indemnity deal exclusively for its members.
NEW MEMBERSHIP BENEFITS FOR ICR FREELANCERS
7 November 2008 - The Institute of Clinical Research (ICR) has announced a specialist insurance and professional indemnity deal exclusively for its members.
The deal, launched at the ICR Freelance Forum this week, offers freelance CRA (clinical research associate) and CTA (clinical trials administrator) members heavily discounted professional indemnity and errors and omissions insurance, starting from £600 – a more than £2,000 saving on most policies.
To establish the exclusive scheme the ICR has joined forces with leading clinical research insurance broker, Miller Insurance Services Limited and specialist professional indemnity insurer, DUAL Corporate Risks. All ICR fellows (FICR), professional (MICR) and registered (RICR) members can apply for cover and will be given the option of spreading the premium over ten monthly instalments.
Rukhsana Shaikh-Zaidi, chair of the ICR Freelance Special Interest Group, is delighted that ICR is offering an additional service to freelancers. She said: “The issue of professional indemnity and personal insurance is increasingly being queried and requested across the industry.
“To be able to offer this deal, with specialist clinical research insurance brokers, will be a huge weight off the shoulders of many CTAs and CRAs.”
The deal was launched at the ICR Freelance Forum held at the Institute’s global headquarters in Bourne End, Buckinghamshire where representatives from Miller Insurance Services Limited and DUAL Corporate Risks introduced the new initiative and addressed member questions.
In addition to the Freelance Forum, ICR provides a number of benefits for its freelance members including an online register where visitors can search for a freelancer with particular skills or therapeutic area of expertise.
In the new year the ICR will also be releasing an updated version of its popular book entitled The ICR Guide to Freelancing. The book includes advice specifically for clinical research freelancers on topics such as setting up your own business, interpersonal and management skills, obtaining insurance and finding work. The book, edited by Helen Glenny, an experienced freelancer herself, is due for release in spring 2009.
For further information about the ICR and the Freelance Special Interest Group, log on to the website at www.icr-global.org/community <http://www.icr-global.org/community> or call 0845 521 0056.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.